Bracco Imaging S.p.a.

Luigi Miragoli

Alessandro Maiocchi

Simona Ghiani

Claudia Cabella

Fabio Tedoldi

Pernille Rose Jensen

Sonia Colombo Serra

Lara Caminiti

Roberta Napolitano

Massimo Visigalli

Federica Buonsanti

Magnus Karlsson

Mathilde H Lerche

Giovanni Valbusa

Lorena Pizzuto

Luisa Poggi

Laura Orio

Chiara Brioschi

Francesco Blasi

Lerche H Mathilde

Luca Venturi

The present invention discloses a solid lipid nanoparticle (SLN) comprising: a) a solid lipid core comprising at least a glyceride and/or at least a fatty acid; b) a mixture of amphiphilic components forming a shell around said core a); c) an alkaline-earth complex with a compound of formula I and/or II:  d) at least a fluorescent dye selected from: a cyanine fluorescent dye and/or a polyetherocyclic compound selected from: coumarin, pyrano, quinoline, pyranoquinoline, indole and pyranoindole derivates in acid form or a pharmaceutically acceptable salt thereof. These nanoparticles allow a prolonged blood circulation half-life, show enhanced photostability and improved fluorescence signal. The dye is preserved from degradation and improves the fluorescent quantum yield.

Fluorescent solid lipid nanoparticles composition and preparation thereof

1-C-1,1-Bis(acetoxy(methyl))-2,2'-cyclopropane of formula (I): The compound can be hyperpolarized and used as a contrast agent inC Magnetic Resonance diagnostic technique (C-MR) for the diagnosis of tumor.

Hyperpolarized 1-13C-1,1-bis(acetoxy(methyl))-2,2'-cyclopropane as metabolic marker for MR

The invention relates to a method of Magnetic Resonance (MR) detection, in particularC-MR detection, by using a diagnostic medium comprising a hyperpolarized ester, in particular ethyl acetoacetate. The method comprises the detection of the MR signal of a hyperpolarizedC carboxylic ester and of its respective hyperpolarized metabolite.

Hyperpolarized esters as metabolic markers in MR

The present invention discloses a solid lipid nanoparticle (SLN) comprising: a) a solid lipid core comprising at least a glyceride and/or at least a fatty acid; b) a mixture of amphiphilic components forming a shell around said core a); c) an alkaline-earth complex with a compound of formula I and/or II: d) at least a fluorescent dye selected from: a cyanine fluorescent dye and/or a polyetherocyclic compound selected from: coumarin, pyrano, quinoline, pyranoquinoline, indole and pyranoindole derivates in acid form or a pharmaceutically acceptable salt thereof. These nanoparticles allow a prolonged blood circulation half-life, show enhanced photostability and improved fluorescence signal. The dye is preserved from degradation and improves the fluorescent quantum yield. 

The present invention relates to paramagnetic solid lipid nanoparticles (pSLNs) comprising an amphiphilic paramagnetic metal chelating moiety selected from: a diazepine derivative of Formula I and a tetraazocyclododecane derivative of Formula (II): being said chelating moiety complexed to a paramagnetic metal ion selected from the group consisting of: Gd(III), Mn(II), Cr(III), Cu(II), Fe(III), Pr(III), Nd(III), Sm(III), Tb(III), Yb(III), Dy(III), Ho(III) and Er(III), or salts thereof. The invention further relates to the process for preparation of said solid lipid nanoparticles comprising amphiphilic complexes of paramagnetic metals (pSLNs) and to the use of pSLNs as MRI contrast agents in the diagnostic field.

Paramagnetic solid lipid nanoparticles (pSLNs) containing metal amphiphilic complexes for MRI

Growing community of inventors

Dovera, Italy

Luigi Miragoli